RXi Pharmaceuticals Corp  

(Public, NASDAQ:RXII)   Watch this stock  
Find more results for RXII
+0.29 (5.69%)
Mar 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.05 - 6.30
52 week 2.51 - 11.20
Open 5.06
Vol / Avg. 994,240.00/333,954.00
Mkt cap 13.50M
P/E     -
Div/yield     -
EPS -10.85
Shares 2.37M
Beta 1.75
Inst. own 2%
Mar 28, 2018
Q4 2017 Rxi Pharmaceuticals Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -47336.84%
Operating margin - -47447.37%
EBITD margin - -47168.42%
Return on average assets -137.70% -73.25%
Return on average equity -212.05% -136.49%
Employees 15 -
CDP Score - -


257 Simarano Dr Ste 101
MARLBOROUGH, MA 01752-3070
United States - Map
+1-508-7673861 (Phone)
+1-508-7673862 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company's development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.

Officers and directors

Robert J. Bitterman Independence Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Geert Cauwenbergh Ph.D. President, Chief Executive Officer, acting Chief Financial Officer, Director
Age: 63
Bio & Compensation  - Reuters
Gerrit Dispersyn Chief Development Officer
Bio & Compensation  - Reuters
Keith L. Brownlie CPA Independent Director
Age: 64
Bio & Compensation  - Reuters
H. Paul Dorman Independent Director
Age: 79
Bio & Compensation  - Reuters
Jonathan E Freeman Ph.D. Independent Director
Bio & Compensation  - Reuters
Curtis A. Lockshin Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters